comprehensive -WSS

comprehensive

author：hotspot 2025-09-30 20:05:50 - browse：774

Biogen announced a new round of cost cuts Tuesday, saying that it plans to save $700 million in operating costs and cut 1,000 jobs by 2025.

The company also released second quarter sales and earnings that handily topped the forecasts of Wall Street analysts. In early morning trading, Biogen shares rose more than 1%.

Biogen is attempting to recover from a series of corporate stumbles, the biggest of which involved the development and launch of the Alzheimer’s drug Aduhelm. The medicine was the first of a new class of disease-modifying Alzheimer’s drugs to be approved by the Food and Drug Administration. But doubts about the quality of the data behind the medicine meant that Medicare wouldn’t pay for it and doctors did not prescribe it. The resulting financial disaster cleaned out Biogen’s executive suite.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： 'Make People Better': The CRISPR babies story you probably don't know

Wikipedia

WSS

Medicaid rebukes states for mistakenly disenrolling children

The FDA must approve intranasal treatments for anaphylaxis

Stem cell treatment guidelines are released by FDA

AstraZeneca chief proposes a novel edit to the drug pricing bill

Stem cell treatment guidelines are released by FDA

How to protect patients from sexual assault

leisure time

comprehensive

focus

Medical leaders decry Supreme Court decision on affirmative action

How a scoliosis diagnosis changed the life of one young dancer

Sports medicine is finally prioritizing gender equality

Advances in CAR

Medical leaders decry Supreme Court decision on affirmative action

The FDA must approve intranasal treatments for anaphylaxis

Tori Bowie and the unacceptable rates of Black maternal death

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

As demand for Covid shots wanes, Moderna seeks its next success

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

focus

JPM: CVS says Medicare Advantage patients are impacting profits

Medicaid rebukes states for mistakenly disenrolling children

The FDA must approve intranasal treatments for anaphylaxis

NIH nominee Bertagnolli will get October confirmation hearing

Crinetics acromegaly drug succeeds in late

Crinetics acromegaly drug succeeds in late

knowledge

focus

Wikipedia

explore